Growing Prevalence of Heavy Menstrual Bleeding (HMB) is Driving the Global Tranexamic Acid Market, are expected to drive market expansion in the near future at a CAGR of 5.38% during the forecast period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Tranexamic Acid Market” that contains information from 2019 to 2035.

The Global Tranexamic Acid Market is estimated to register a CAGR of 5.38% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Tranexamic Acid Market— include Ferrero International Pfizer Inc, Fresenius Kabi Usa, LLC, Teva Pharmaceutical Industries Ltd, MAXWELLIA Ltd, Aurobindo Pharma Usa, Sun Pharmaceutical Industries Ltd, APOTEX Inc, Ferring Pharmaceuticals, Nordic Pharma, Inc, EXELA Pharma Sciences LLC and among others.

Market Highlights

The Global Tranexamic Acid Market is estimated to register a CAGR of 5.38% during the forecast period and is estimated to reach USD 1.86 Billion by 2035.

The rising number of surgical procedures worldwide is a key factor driving the growth of the global tranexamic acid market. The increasing prevalence of chronic diseases such as cardiovascular disorders, orthopedic conditions, and cancer has significantly contributed to the rising demand for surgical interventions. As more patients undergo surgeries ranging from coronary artery bypass grafting (CABG) and joint replacements to tumor resections and cesarean deliveries, the need for effective blood management solutions has intensified. Tranexamic acid has become a cornerstone in surgical settings, helping to minimize excessive blood loss and improve surgical outcomes. The World Health Organization (WHO) estimates that over 310 million major surgeries are performed annually worldwide, with the number expected to rise due to advancements in medical technology and improved access to healthcare.

One of the major advantages of tranexamic acid in surgical applications is its ability to inhibit fibrinolysis, thereby reducing intraoperative and postoperative bleeding. In orthopedic surgeries, particularly total knee arthroplasty (TKA) and total hip arthroplasty (THA), blood loss can be substantial, leading to increased dependency on blood transfusions. Studies have shown that administering tranexamic acid significantly reduces transfusion requirements, resulting in lower risks of complications such as infections and immunological reactions. For example, a 2023 study published in JAMA Surgery revealed that tranexamic acid reduced blood transfusion rates by over 40% in patients undergoing major joint replacement surgeries, solidifying its role as a standard hemostatic agent.

Access Full Report @ https://www.marketresearchfuture.com/reports/tranexamic-acid-market-33541

Segment Analysis

The Global Tranexamic Acid Market has been segmented based on By Formulation Type, By Application, By End User.

Based on the Formulation Type, the Global Tranexamic Acid market has been bifurcated into Oral, Injectable, and Topical. The Oral segment accounted for the largest market share of USD 0.49 Billion in 2024 and is likely to register a CAGR of 5.83% during the projected period. On the other hand, Injectable segment will likely register a CAGR of 5.02% during the projected period. 

Oral tranexamic acid is one of the most widely used formulations due to its ease of administration, high patient compliance, and affordability. This formulation is extensively prescribed for the treatment of heavy menstrual bleeding (menorrhagia), which affects a significant proportion of women globally. According to the American College of Obstetricians and Gynecologists (ACOG), nearly one in three women experience excessive menstrual bleeding, and oral tranexamic acid has emerged as an effective first-line treatment option. Unlike hormonal therapies, which may have long-term side effects, tranexamic acid offers a safer alternative with minimal hormonal interference. Additionally, oral formulation is commonly used to reduce postoperative bleeding in dental, orthopedic, and cardiovascular surgeries, significantly lowering the need for blood transfusions.

The affordability and availability of tablet and capsule formulations make them a preferred choice in developing economies, where access to advanced surgical interventions is often limited. For instance, in India and Southeast Asian countries, oral tranexamic acid is a widely prescribed medication in gynecology and general surgery departments. Additionally, the growing awareness of self-medication and over the counter (OTC) drugs has fueled the demand for oral formulations. Several pharmaceutical companies, including Sanofi and Pfizer, are expanding their product lines to cater to the increasing demand for this formulation.

Furthermore, the market for oral tranexamic acid is expected to witness significant growth due to expanding research in combination therapies. Several studies have suggested that combining tranexamic acid with nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance its efficacy in treating postoperative bleeding and menstrual disorders. Additionally, research is being conducted on extended-release formulations to improve patient adherence and reduce the frequency of dosing. These advancements are expected to enhance the adoption of oral tranexamic acid in both hospital and outpatient settings.

Based on the Application, the Global Tranexamic Acid market has been classified into Menorrhagia, Surgical Bleeding Control, Trauma and Injury, Hereditary Angioedema (HAE), Postpartum Hemorrhage, and Others. The Menorrhagia segment accounted for the largest market share of USD 0.61 in 2024 and is likely to register a CAGR of 5.88% during the projected period. On the other hand, the surgical bleeding control segment will likely register a CAGR Of 4.76% during the projected period.

Menorrhagia, or excessive menstrual bleeding, is one of the most common indications for tranexamic acid (TXA) usage, significantly impacting millions of women worldwide. It is characterized by heavy or prolonged menstrual bleeding that can lead to iron deficiency anemia, fatigue, and reduced quality of life. According to the American College of Obstetricians and Gynecologists (ACOG), nearly one in five women experience heavy menstrual bleeding, making it a significant public health concern. Tranexamic acid works by inhibiting plasminogen activation and stabilizing blood clots, thereby reducing menstrual blood loss by up to 50% in affected individuals. Unlike hormonal treatments such as oral contraceptives or intrauterine devices (IUDs), TXA provides a non-hormonal alternative, making it particularly beneficial for patients who cannot tolerate hormonal therapies. The increasing prevalence of menorrhagia and growing awareness about non-hormonal treatment options have driven significant demand for TXA in gynecological care.

The global rise in adolescent and reproductive-age women seeking effective treatments for menorrhagia has led to an increased preference for tranexamic acid tablets, which offer ease of administration and minimal side effects compared to invasive procedures such as endometrial ablation or hysterectomy. According to the National Health Service (NHS) in the UK, TXA has become a first-line pharmacological option for managing heavy menstrual bleeding, particularly for patients who wish to preserve their fertility. Additionally, research has indicated that TXA does not increase the risk of venous thromboembolism (VTE), making it a safer option compared to estrogen-containing medications. The growing shift towards evidence-based, patient-friendly treatment options has encouraged healthcare providers to incorporate TXA into routine gynecological management protocols.

Based on the End User, the Global Tranexamic Acid market has been classified into Hospitals & Clinics, Ambulatory Surgical Centers, and Others. The hospitals segment accounted for the largest market share of USD 0.46 in 2024 and is likely to register a CAGR of 5.23% during the projected period. On the other hand, the Ambulatory Surgical Centers (ASCs) segment will likely register a CAGR of 4.96% during the projected period. 

Hospitals and clinics represent the largest end-user segment of the global tranexamic acid (TXA) market due to the widespread use of TXA in surgical procedures, trauma management, and obstetric emergencies. These healthcare facilities rely on TXA to prevent and control excessive bleeding in various medical interventions, making it a crucial component of hospital formularies. TXA is extensively used in major surgical departments, including cardiology, orthopedics, gynecology, and neurosurgery, where blood loss management is critical. According to the American Society of Hematology (ASH), hospitals have reported a significant reduction in blood transfusion rates, by approximately 30-50%, in surgical patients administered with TXA, highlighting its essential role in blood conservation strategies.

In emergency and trauma care settings, hospitals deploy TXA as a first-line intervention for hemorrhagic shock. The CRASH-2 trial, conducted by the London School of Hygiene & Tropical Medicine, demonstrated that administering TXA within three hours of severe trauma reduced mortality by nearly 15%. This has led to TXA being included in hospital emergency protocols and pre-hospital ambulance services worldwide. Additionally, major health organizations such as the World Health Organization (WHO) and the National Institute for Health and Care Excellence (NICE) recommend TXA administration in emergency settings, further strengthening its adoption in hospitals.

Regional Analysis

Based on the Region, the global Tranexamic Acid is segmented into North America, Europe, Asia-Pacific and Rest of the World. The North America dominated the global market in 2024, while the Asia Pacific is projected to be the fastest–growing segment during the forecast period.

Major demand factors driving the North America market are North America dominates the global tranexamic acid (TXA) market, driven by advanced healthcare infrastructure, a high volume of surgical procedures, and increasing awareness regarding blood loss management. The United States and Canada have been at the forefront of TXA adoption due to the rising number of trauma-related injuries, increasing surgical interventions, and supportive regulatory policies. The Centers for Disease Control and Prevention (CDC) reports that over 50 million major surgeries are performed annually in the U.S., many of which require effective perioperative blood management strategies. TXA has gained widespread use in orthopedic, cardiac, trauma, and obstetric surgeries, leading to reduced blood transfusion rates and improved patient outcomes.

Additionally, government initiatives promoting patient blood management (PBM) programs have significantly contributed to TXA's market expansion. The region's high incidence of trauma cases and emergency care admissions has further accelerated the demand for TXA. According to the National Highway Traffic Safety Administration (NHTSA), more than 6 million traffic accidents occur annually in the U.S., with a substantial number resulting in life-threatening hemorrhagic injuries. TXA has become a standard treatment in prehospital trauma care, with paramedics administering it to reduce the risk of mortality from excessive bleeding. Moreover, the U.S. military has incorporated TXA into battlefield medicine protocols, leveraging its life-saving potential in combat zones and mass casualty incidents.

Key Findings of the Study

• The Global Tranexamic Acid Market is expected to reach USD 1.86 Billion by 2035, at a CAGR of 5.38% during the forecast period.


• The Asia Pacific region accounted for the fastest growing in the global market.


• Based on Application, the Menorrhagia segment was attributed to holding the largest market in 2024.


• Ferrero International Pfizer Inc, Fresenius Kabi Usa, LLC, Teva Pharmaceutical Industries Ltd, MAXWELLIA Ltd, Aurobindo Pharma Usa, Sun Pharmaceutical Industries Ltd, APOTEX Inc, Ferring Pharmaceuticals, Nordic Pharma, Inc, EXELA Pharma Sciences LLC and among others are the key market players.